The Role of Long Non-coding RNA (NKILA and LINC00993) as Tumour Biomarkers in Breast Cancer

Abstract

<title>Abstract</title> Background Breast cancer) BC) is the most frequent cancer among women and the second most common cause of cancer deaths worldwide. Long non-coding RNAs (NKILA and LINC00993) are downregulated in BC and can have potential use as a novel tumor biomarker. Aim of the work: To investigate the Long non-coding RNA (NKILA and LINC00993) and cytokines (NF-KB and CXCL-1) as potential biomarkers in breast cancer. Subjects and methods: This case-control study included sixty-four pairs of surgically resected human breast cancer tissues and adjacent breast tissues. Expressions of LncRNAs (NKILA, LINC00993) and (NFκB, CXCL1) cytokines were detected using real-time quantitative polymerase chain reaction (qPCR) analysis, Results There was a significant decrease in LncRNAs (NKILA, LINC00993) levels in tumor tissue compared to normal tissue (P &lt; 0.001). Also, there was a significant increase in NF-KP and CXCL1 levels in tumor tissue compared to normal tissue (P &lt; 0.001). ROC curve analysis indicated that the LncRNAs (NKILA, LINC00993) expression levels could be considered a promising marker for the diagnosis of breast cancer patients with a sensitivity (90.6%, 92.2% respectively). Also, cytokines (NF-KB and CXCL-1) expression levels could be considered a promising marker for the diagnosis of breast cancer patients with a sensitivity and specificity of 87.5%, 89.1% respectively). Conclusion These findings suggest that LncRNAs (NKILA, LINC00993) and cytokines (NF-KB and CXCL-1) can be used as novel biomarkers for breast cancer.